Author:
Philippe L,Helias P,Puyraveau M,Boulahdour H,Deconinck E,Daguindau E
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference15 articles.
1. Botto B, Bellò M, Ciochetto C, Audisio E, Boccomini C, Chiappella A et al. Radioimmunotherapy followed by BEAM conditioning regimen and autologous transplantation is effective and safe in high risk relapsed/resistant non Hodgkin’s lymphoma: a single institution experience. Haematologica 2010; 95: 614.
2. Wondergem MJ, Zijlstra JM, de Rooij M, Visser OJ, Huijgens PC, Zweegman S et al. Improving survival in patients with transformed B cell non-Hodgkin lymphoma: consolidation with 90Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation. Br J Haematol 2012; 157: 395–397.
3. Terriou L, Gasmi H, Manier S, Plantier I, Wetterwald M, lionne-Huyghe P et al. 90-Yttrium ibritumomab tiuxetan (Zevalin) and BEAM chemotherapy (Z-BEAM) vs BEAM for autologous stem cell transplantation in lymphoma: toxicity and long term outcome from a retrospective multicentric study of 123 patients. ASH Annu Meet Abstr 2012; 120: 2726.
4. Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 2014; 123: 2953–2959.
5. Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012; 118: 4706–4714.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献